Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420836
Status:
COMPLETED
Last Update Posted:
2007-01-11
First Post:
2007-01-10
Brief Title:
Tobramycin Administered by eFlow Rapid Nebulizer Pharmacokinetic Study
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow Rapid Electronic Nebulizer no Compressor vs PARI LC PLUSTM Jet Nebulizer With Compressor in Cystic Fibrosis Subjects
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study assesses the aerosol delivery characteristics measured by nebulization time serum and sputum tobramycin pharmacokinetic parameters and safety of tobramycin administered for inhalation by PARI eFlow rapid electronic nebulizer no compressor vs PARI LC PLUS Jet Nebulizer with compressor in subjects with cystic fibrosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None